Show simple item record

dc.contributor.authorSánchez-Alonso, Santiago
dc.contributor.authorSetti-Jerez, Giulia
dc.contributor.authorArroyo, Montserrat
dc.contributor.authorHernández, Tathiana
dc.contributor.authorMartos, Mª Inmaculada
dc.contributor.authorSánchez-Torres, Jose Miguel
dc.contributor.authorColomer, Ramon
dc.contributor.authorRamiro, Almudena R 
dc.contributor.authorAlfranca, Arantzazu
dc.identifier.citationJ Immunother Cancer. 2020; 8(2):e001187es_ES
dc.description.abstractLung cancer is one of the most frequent malignancies in humans and is a major cause of death. A number of therapies aimed at reinforcing antitumor immune response, including antiprogrammed cell death protein 1 (anti-PD-1) antibodies, are successfully used to treat several neoplasias as non-small cell lung cancer (NSCLC). However, host immune mechanisms that participate in response to anti-PD-1 therapy are not completely understood. We used a syngeneic immunocompetent mouse model of NSCLC to analyze host immune response to anti-PD-1 treatment in secondary lymphoid organs, peripheral blood and tumors, by flow cytometry, immunohistochemistry and quantitative real-time PCR (qRT-PCR). In addition, we also studied specific characteristics of selected immune subpopulations in ex vivo functional assays. We show that anti-PD-1 therapy induces a population of circulating T follicular helper cells (cTfh) with enhanced B activation capacity, which participates in tumor response to treatment. Anti-PD-1 increases the number of tertiary lymphoid structures (TLS), which correlates with impaired tumor growth. Of note, TLS support cTfh-associated local antibody production, which participates in host immune response against tumor. These findings unveil a novel mechanism of action for anti-PD-1 therapy and provide new targets for optimization of current therapies against lung cancer.es_ES
dc.description.sponsorshipThis work was supported by grants to AA: FIS PI15/01491 and CIBER CARDIOVASCULAR from the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria del Instituto de Salud Carlos III with co-fundingfrom the Fondo Europeo de Desarrollo Regional; FEDER).es_ES
dc.publisherBMJ Publishing Group es_ES
dc.titleA new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderEuropean Regional Development Fund 
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBER
dc.identifier.journalJournal for immunotherapy of canceres_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Biología de linfocitos Bes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto
Acceso Abierto
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
This item is licensed under a: Atribución-NoComercial 4.0 Internacional